Masonic Cancer Center, University of Minnesota  
Blood and Marrow Transplantation Program  
 
 
 
Transplantation of Umbilical Cord Blood from Unrela ted Donors in 
Patients With  Hematological Diseases Using a Non -Myeloablative 
Preparative Regimen  
MT2015 -17 
CPRC # 2015LS 149 
 
 
 
Principal Investigator:  
 
Margaret L.MacMillan, MD  
 
 
Collaborators : 
John E. Wagner, MD  
 
 
Bruce R. Blazar, MD  
Kathryn Dusenbery, MD  
Jeffrey Miller, MD  
Daniel J. Weisdorf, MD 
David McKenna, Jr, MD  
 
 
Biostatistician:  
Qing Cao , MS 
 
 
Version Date:  
April 25, 2022  
 
Confidential  
  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 2 of 36  CPRC #2015LS149  Revision History  
 
Revision 
Number  Version 
Date  Revision Summary  Consent 
Change?  
 10/27/2015  original to CPRC   
 1/27/2016  In response to CPRC stips, original to IRB  n/a 
 12/29/2016  Updated disease eligibility and general study 
inclusion/exclusion criteria to match institutional  
standard language  
Updated link to Cancer Center DSMP  Yes 
 2/22/2018  Section 2: Updated to clarify standard of care 
procedures   
 04/25/2022  Updated Study committee  
Minor template edits: removed eligibility checklist,  
updated dsmp link, updated reference to cord blood 
IND sponsor  Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PI Contact Information:  
Margaret L. MacMillan, MD, MSc, FRCPC  
Professor of Pediatrics  
Blood and Marrow Transplant Program  
University of Minnesota  
MMC 484   
420 Delaware Street SE  
Minneapolis, MN 55455  
612 626 -2961 (phone)  
612-626-2815 (fax)  
macmi002@umn.edu (email)   
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 3 of 36  CPRC #2015LS149  Table of Contents  
 
Study Synopsis  ................................................... ................................................... ..............................  5 
Treatment Plan  ................................................... ................................................... ...............................  7 
1 Study Objectives  ................................................... ................................................... ....................  8 
1.1 Primar y Objective ................................................... ................................................... ...........  8 
1.2 Secondary Objectives  ................................................... ................................................... ... 8 
1.3 Transplant Related Objectives  ................................................... ........................................  8 
2 Background and Rationale  ................................................... ................................................... ... 8 
3 Study Design  ................................................... ................................................... ........................  11 
4 Patient Selection  ................................................... ................................................... ..................  11 
4.1 Inclusion Criteria  ................................................... ................................................... ..........  11 
4.1.1  Age, Performance Status, and Graft Criteria  ................................................... ...... 11 
4.1.2  Eligible Diseases  ................................................... ................................................... .. 12 
4.1.3  Additional Criteria for Bulky Disease (lymphomas)  ..............................................  14 
4.1.4  Organ Function Criteria  ................................................... ..........................................  14 
4.2 Exclusion Criteria  ................................................... ................................................... .........  15 
5 Patient Registration In OnCore  ................................................... .............................................  16 
6 Treatment Plan  ................................................... ................................................... .....................  16 
6.1 Preparative Regimen (Arm 1 - no ATG)  ................................................... ......................  17 
6.2 Preparative Regimen with ATG  ................................................... ....................................  18 
6.3 GVHD Prophylaxis (begin Day -3) ................................................... ...............................  19 
6.3.1  Sirolimus  ................................................... ................................................... ................  19 
6.3.2  Mycophenolate Mofetil (MMF)  ................................................... ..............................  20 
6.4 Umbilical Cord Blood Thaw and Infusion (Day 0)  ................................................... ...... 20 
6.5 Supportive Care  ................................................... ................................................... ...........  21 
6.6 Management of Slow Engraftment or Graft Failure  ................................................... ... 21 
6.7 Follow -up ................................................... ................................................... .......................  21 
7 Expected Toxicities of the Treatment Plan  ................................................... .........................  21 
7.1 Preparative Regimen ................................................... ................................................... ... 21 
7.2 GVHD Prophylaxis  ................................................... ................................................... .......  23 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 4 of 36  CPRC #2015LS149  7.3 UCB Cell Infusion ................................................... ................................................... .........  24 
8 Clinical Care Activities ................................................... ................................................... .........  25 
9 Adverse Event Monitoring, Documentation and Reporti ng .................................................  26 
9.1 Event Documentation  ................................................... ................................................... .. 26 
9.2 Adverse Event Reporting  ................................................... ...............................................  26 
10 Study Data Collection and Monitoring  ................................................... .............................  27 
10.1  Data Collection  ................................................... ................................................... .............  27 
10.2  Data and Safety Monitoring  ................................................... ...........................................  27 
10.3  Study Related Monitoring  ................................................... ............................................. . 27 
10.4  Record Retention  ................................................... ................................................... .........  27 
11 Statistical Considerations  ................................................... ..................................................  28 
11.1  Primary, Secondary and Transplant -Related Endpoints and Study Design  .............  28 
11.2  Statistical Analysis  ................................................... ................................................... .......  28 
11.2.1  Analysis of Primary Endpoint  ................................................... ................................  28 
11.2.2  Analysis Of Secondary and Transplant Related Object ives  ...............................  29 
11.3  Rationale for Sample Size  ................................................... .............................................  29 
11.4  Safety Monitoring  ................................................... ................................................... .........  30 
12 Conduct of the Study  ................................................... ................................................... .......  30 
12.1  Record Retention  ................................................... ................................................... .........  30 
12.2  Ethical Considerations  ................................................... ...................................................  30 
12.3  Informed Consent  ................................................... ................................................... ........  30 
13 References  ................................................... ................................................... ........................  31 
Appendix I – Eligibility Checklist  ................................................... ...................................................  34 
Appendix II – Karnofsky Performance Status and Lansky Play Score  ......................................  35 
Appendix III – TBI Guidelines  ................................................... ................................................... .... 36 
 
  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 5 of 36  CPRC #2015LS149  Study Synopsis  
Transplantation of Umbilical Cord Blood from Unrela ted Donors in Patients 
With Hematological Diseases Using a Non -Myeloablative Preparative Regimen  
MT2015 -17 
Study Design:  This is a  phase II trial using a non -myeloablative cyclophosphamide/ 
fludarabine/tot al body irradiation (TBI) preparative regimen with 
modifications based on factors including diagnosis,  disease status, and 
prior treatment.  Single or double unit selected ac cording to current 
University of Minnesota umbilical cord blood graft selection al gorithm . 
 
This study uses a  Minimax two -stage phase II design.  Stage 1 will enroll 
110 patients.  If 54 or fewer develop GVHD, 45 additional patients  will be 
enrolled.  After stage 2, if 71 or fewer out of 155 enrolled d evelop GVHD, 
CSA/Sirolimus  will be considered worthy of further consideration.  
 
Primary Objective:  Estimate probability of grade II -IV acute GVHD  at Day 100  
 
Secondary Objective s: • Incid ence of Day 100 grade III -IV acute GVHD  
• Transplant related  mortality (TRM) at 6 months  
• Chimerism at Day 21, 100,180 and 365  
• Incidence of neutrophil engraftment by Day 42  
 
Transplant Related 
Objectives:  • Incidence of platelet engraftment by six months  
• Incidence of one year chronic GVHD  
• Probability of one and two year overall survival  
• Probability of one and two year progression free su rvival (PFS)  
• Incidence of one and two year relapse or disease pr ogression  
 
Eligible Diseases:  All diseases listed below are advanced hematologic malignancies not 
curable by conventional chemotherapy.  Refer to sec tion 4.1.2 for specific 
criteria.  
• Acute Leukemias  
• Acute myeloid leukemia  
• Acute lymphoblastic leukemia/lymphoma  
• Biphenotypic/Undifferentiated/Prolymphocytic Leukem ias  
• MRD positive leukemia  
• Leukemia or MDS in aplasia  
• Burkitt’s lymphoma  
• Relaps ed T-Cell Lymphoma  
• Natural killer cell malignancies  
• Chronic myelogenous leukemia  in chronic or accelerated phase, or 
CML blast crisis in morphological remission (<5% bl asts)    
• Myelodysplastic syndrome  
• Large -cell lymphoma, Hodgkin lymphoma and multiple mye loma  
• Relapsed Chronic lymphocytic leukemia/small lymphocytic lymp homa 
(CLL/SLL), marginal zone B -cell lymphoma, follicular lymphoma  
• Lymphoplasmacytic lymphoma, mantle -cell lymphoma, prolymphocytic 
leukemia  
• Relapsed Multiple Myeloma  
• Plasma Cell Leukemia  
• Bone marrow failure syndromes, except for Fanconi a nemia  
• Myeloproliferative Neoplasms/Myelofibrosis  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 6 of 36  CPRC #2015LS149  • Other Leukemia Subtypes -  with the approval of two members of the 
study committee   
Age. PS,  and UCB 
Graft Requirements : • <70 years old with no matched 5/6  or 6/6 sibling donor - patients ≥ 70 
but ≤ 75 are eligible if the co -morbidity score is ≤ 2 
(http://www.qxmd.com/calculate -online/hematology/hct -ci) 
• Karnofsky score ≥ 70% (≥ 16 years) or Lansky score ≥ 50 (< 16 years)  
• UCB graft to be selected according to  current University of Minnesota 
umbilical cord blood graft selection algorithm  
 
 
Other Inclusion Criteria:  • adequate liver and renal function per section 4.1.4  
• absence of decompensated congestive heart failure, or uncontrolled 
arrhythmia and left ventricular ejection fraction ≥ 40% 
• DLCO , FEV 1, FVC  > 40% predicted, and absence of O 2 requirements  
 
Exclusion Criteria:  • pregnant or breastfeeding  
• untreated active infection  
• Active  HIV infection or known HIV positive serology  
• Less than 3 months since prior myeloablative transp lant 
• Evidence of progressive disease by imaging modaliti es or biopsy 
- persistent PET activity, though possibly related to  lymphoma, is 
not an exclusion criterion in the absence of CT cha nges 
indicating progression.  
• CML in blast crisis  
• large cell lymphoma, mantle cell lymphoma and Hodgk in 
lymphoma that is progressive on salvage therapy  
• Active central nervous system malignancy  
 
Enrollment:  15-25 patients per year  over 6-10 years  for a total of 163 patients  
 
  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 7 of 36  CPRC #2015LS149  Treatment Plan  
Disease/Prior Treatment Status   Preparative Regimen  
CY/FLU/TBI, no ATG 
hematological diseases with prior autologous 
transplant, ≥ 2 cycles of multi -agent 
chemotherapy or severely 
immunosuppressive therapy in the last 3 
months    
• cyclophosphamide 50 mg/kg Day -6 
• fludarabine 30 mg/m2 Days -6 to -2  
• TBI 200cGy Day -1 
 
 
CY/FLU/TBI, ATG   
hematological diseases with prior autologous 
transplant > 12 months or ≤ 1 cycle of multi -
agent chemotherapy or no 
immunosuppressive chemotherapy in the last 
3 months    
• cyclophosphamide 50 mg/kg Day -6 
• fludarabine 30 mg/m2 Days -6 to -2 
• TBI 200cGy Day -1 
• equine ATG 15 mg/kg bid Days -6 to -4 
 
 
     UCB  
     I nfusion            key follow -up time points  
              
              
Day -6      -5      -4      -3      -2      -1       0        21      28       42       60        180     360     720 
  GVHD prophylaxis:   
MMF  through Day +30 or 7 days after engraftment  (whichever is earlier)  
   Sirolimus  through Day +100, taper until Day +180   Preparative Regimen from above  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 8 of 36  CPRC #2015LS149  1 Study Objectives  
1.1 Primary Objective  
The primary objective is to e stimate the probability of grade II -IV acute 
GVHD at Day 100 after unrelated donor umbilical cord blood 
transplantation using  a non -myeloablative preparative regimen along 
with Sirolimus/MMF for GVHD prophylaxis in persons with hematologic 
malignancies.  
1.2 Secondary Objectives  
Secondary objectives are:  
• Incidence of grade III -IV acute GVHD at 100 days  
• Transplant related  mortality (TRM) at 6 months  
• Chimerism at Day 21, 100,180 and 365  
• Incidence of neutrophil engraftment by Day 42 
1.3 Transplant Related Objectives  
• Incidence of platelet engraftment by six months  
• Incidence  of one year chronic GVHD  
• Probability of one and two year overall survival (O S) 
• Probability of one and two year  progression free survival (PFS)   
• Incidence of one and two year relapse or disease pr ogression  
2 Background and Rationale  
Umbilical cord blood (UCB) is now an established alte rnative donor type for 
allogeneic transplantation.  The advantages of UCB transplantation included, 
but not limited to, rapid availability, less restric tive HLA -selection criteria, no 
risk for the donor,  and relative low risk of graft -versus -host disease (GVHD). 
The main limitations of UCB are limited stem cell c ontent, delayed engraftment 
potentially increasing the risk of infections  and morbidity.  
Our institution has led several critical advances in the UCB transplant field . Our 
approach and clinical outcomes have now been reprodu ced worldwide as 
evidenced by reports from Center for International Blood and Marrow 
Transplant and Research (CIBMTR) (1) the Blood and Marrow Transplant 
Clinical Trials Network (BMT -CTN) (2) and by the Societé Française de Greffe 
de Moelle Osseuse et Therapie  Cellulaire and Eurocord (3-5).  In one of these 
reports, the outcomes after UCB transplantation were  shown to be  similar to 
other donor types  (1).  
 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 9 of 36  CPRC #2015LS149  The University of Minnesota platform consists of cyclo phosphamide 50 mg/m2, 
fludarabine 200 mg/m2 divided in 5 days and total body irradiation (TBI) 200 
cGy with cyclosporine A (CsA) and mycophenol ate mofetil (MMF) immune 
suppression.  This treatment platform has been shown to support sin gle and 
double UCB transplantation resulting in sustained d onor engraftment > 90%, 
transplant related mortality ( TRM ) between 20 -30%, and long term disease free 
survival (DFS ) in 25 -50% depending on disease stage and the presence of c o-
morbid condition prior to transplantation. (6)  Building upon this platform our 
groups has focused our research efforts on methods tha t will ultimately result 
in improved immune reconstitution (7-9) .  Our hypothesis is that reducing the 
risk of GVHD after UCB transplantation would facilita te the reconstitution of 
lymphocyte  subsets and result in lower risk of infections and rela pse, potentially 
improving survival. Recent reports by our group demo nstrated the critical 
influence of therapeutic cyclosporine A level in the f irst month post -
transplantation (7), the superior effectiveness in suppressing acute GV HD of 
MMF 3g/day (8), and the promising early results of the adoptive tr ansfer of UCB -
derived natural regulatory T cells (nTreg) (9).  More recently we studied the 
safety and efficacy of the combination of sirolimus and MMF as immune 
suppressive regimen  in a subset of patients.  
The mTor inhibitor sirolimus has potential anti -leukemia (10) and anti -viral 
activity (11).  As compared to calcineurin inhibitors, sirolimus  has a different 
toxicity profile with low risk of kidney dysfunction, h ypertension and seizures 
but it may cause hypertriglyceridemia, skin rash and,  at least in lung transplant 
cases, interstitial pneumonia.  
In matched related dono rs and in UCB transplantation the combination of 
sirolimus with tacrolimus and rabbit ATG resulted on  a risk of GVHD of < 20% 
(12, 13).  In unrelated donor transplantation the combination o f sirolimus with 
tacrolimus and MMF resulted in a risk of acute GVHD o f 47% (14). In haplo -
identical transplantation, sirolimus  with MMF and rabbit ATG results in 35% risk 
of acute GVHD and showed rapid reconstitution of nT reg cells (15).  In contrast, 
studies combining sirolimus with CsA (16) or sirolimus with MMF (17) in adult 
donors were terminated due to excessive acute GVHD.  The combination of 
sirolimus with tacrolimus has a high risk of thromboti c microangiopathy (12) 
and, when used in combination with busulfan based c onditioning regimen, with 
excessive risk of veno -occlusive disease of the liver (12, 18).  Taken together, 
these data suggest that sirolimus/MMF with or without  ATG may be a suitable 
immune suppression regimen in specific sub sets.  
 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 10  of 36  CPRC #2015LS149  In pilot in the setting of UCB transplantation, rec ipients of ex vivo expanded 
UCB derived -nTreg were treated with sirolimus/MMF immune suppres sion that 
favors the survival of this important T -cell subset (19).  As the combination of 
sirolimus/MMF has potential advantages over  calcineurin inhibitor -based 
regimens, we modified our local protocol to incorpo rate this immune 
suppression regimen and monitor ed patient s for increased risk of severe 
GVHD.  As per our institutional practice we allowed for the co-administration of 
equine  ATG in a subset of patients who were considered high  risk for graft 
rejection.  Our preliminary data comparing sirolimus/MMF ± ATG vs CsA/MMF 
± ATG is summarized in the table below. Overall this  immune suppression 
regimen resulted in similar incidence of engraftment , acute GVHD  and non-
relapse mortality.  However, before we can definitively adopt this immu ne 
suppression regimen as our new standard of care, we n eed better define its 
safety and efficacy profile in larger numbers of pati ents.  
Group  N Grade II -IV 
AGVHD  
(95% CI)  ANC  
(95% CI)  NRM  
(95% CI)  
Cy/Flu(40mg)/TBI±ATG + 
CsA/MMF  157 42% (34 -50%)  95% (92 -98%)  24% (17 -31%)  
Cy/Flu(40mg)/TBI±ATG + 
Siro/MMF  11 27% (2 -52%)  82% (59 -100%)  27% (2 -52%)  
Cy/Flu(30mg)/TBI±ATG + 
Siro/MMF  37 35% (19 -54%)  81% (69-93%)  35% (17 -53%)  
 
Experimental Component  
Our non -myeloablative UCB transplant platform is well establ ished.  Despite 
outcomes similar to other donor types there is ample room for improvement. 
Our preliminary data on the sirolimus /MMF ± ATG are promising.  The rationale 
for the development of this immune suppression is tha t in contrast to CsA -
based regimens, sirolimus is supportive  of nTreg cells survival potentially 
reducing risk of acute and chronic GVHD and ultimately  promoting immune 
reconstitution.  Consistent with our approach of progressive changes to our 
platform we will further characterize the safety and  efficacy of sirolimus/MMF 
immune suppression in the setting of non -myeloablative UCB transplantation.  
Standard of Care   
All pre-and post -transplant testing, graft source, chemotherapy and supportive 
measures listed in this protocol are standard of care but are  part of the data 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 11  of 36  CPRC #2015LS149  elements necessary to determine the long -term outcomes of the sirolimus/MMF  
immune suppression regimen.  
3 Study Design  
This is a single institution phase II study of minima lly manipulated umbilical 
cord blood transplantation after a non -myeloablative chemo/radiation 
preparative regimen in persons with one of several h ematologic ma lignancies.  
 
This study uses a  Minimax two -stage phase II design.  Stage 1 will enroll 110 
patients. If 54 or fewer develop GVHD, 45 additional  patients will be enrolled.  
After stage 2, if 71 or fewer out of 155 enrolled d evelop GVHD,   CSA/Sirolimus 
will be considered worthy of further consideration.  
The primary objective of this study is to estimate th e probability of grade II -IV 
acute GVHD at Day 100 and provide support that use of Sirolimus/MMF is  not 
worse at preventing GVHD than CsA/MMF  after unrelated donor umbilical cord 
blood transplantation.  Secondary objectives includ e incidence of neutrophil 
engraftment by Day 42, incidence of grade III -IV acute GVHD, incidence of 
transplant -related mortality and chimerism at Day 21  and 3, 6 and 12 months 
post-transplant.  
4 Patient Selection  
Study entry is open to persons less than 70 years of ag e (refer to for additional 
eligibility ≥ 70 years, but ≤75 years of age), regardless of gender, race or ethni c 
background.  While there will be every effort to see k out and  include females 
and minority patients, the patient population is exp ected to be no different than 
that of similar studies at the University of Minneso ta. 
4.1 Inclusion Criteria 
4.1.1  Age, Performance Status,  and Graft Criteria  
• <70 years of age  with no matched 5/6 o r 6/6 sibling donor - 
patients ≥ 70 and ≤ 75 years of age may be eligible if they have 
a Co-Morbidity  score ≤ 2  - (http://www.qxmd.com/calculate -
online/hematology/hct -ci) 
• Karnofsky score ≥ 70% (≥ 16 years) or Lansky score  ≥ 50 (< 16 
years)  - refer to appendix II  
• UCB graft selected according to current University of  Minnesota 
umbilical cord blood graft selection algorithm  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 12  of 36  CPRC #2015LS149  4.1.2  Eligible Diseases 
All diseases listed below are advanced hematologic ma lignancies 
not curable by conventional chemotherap y.  Responses to 
conventional treatment range from zero to 30% but ar e typically 
short lived [25].  
Acute Leukemias:  Must be in remission by morphology (<5% 
blasts). Note cytogenetic relapse or persistent disease without  
morphologic relapse is acceptable.  Also a small percen tage of 
blasts that is equivocal between marrow regeneration  vs. early 
relapse are acceptable provided there are no associated  
cytogenetic markers consistent with relapse.  
Acute Myeloid Leukemia (AML)  and related precursor 
neoplasms: 2nd or greater complete remission (CR); first 
complete remission (CR1) in patients > 60 years old; CR1 in ≤ 60 
years old that is NOT considered as favorable -risk.  
Favorable risk AML is defined as having one of the fol lowing: 
• t(8,21) without cKIT mutation  
• inv(16) or t(16;16) without cKIT mutation  
• Normal karyotype with mutated NPM1 and wild type FL T-ITD 
• Normal karyotype with double mutated CEBPA  
• Acute prolymphocytic leukemia (APL) in first molecular  
remission at t he end of consolidation  
Acute lymphoblastic leukemia (ALL)/lymphoma: second o r 
greater CR; CR1 unable to tolerate consolidation ch emotherapy 
due to chemotherapy -related toxicities; CR1 high -risk ALL.  
High risk ALL is defined as having one of the followin g: 
• Evidence of high risk cytogenetics, e.g. t(9;22), t(1; 19), 
t(4;11), other MLL rearrangements, IKZF1  
• 30 years of age or older at diagnosis  
• White blood cell counts of greater than 30,000/mcL (B -ALL) 
or greater than 100,000/mcL (T -ALL) at diagnosis  
• CNS leukemia involvement during the course of diseas e 
• Slow cytologic response (>10% lymphoblasts in bone 
marrow on Day 14 of induction therapy)  
• Evidence of persistent immonophenotypic  or molecular 
minimal residual disease (MRD) at the end of inductio n and 
consolidation therapy  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 13  of 36  CPRC #2015LS149  Biphenotypic/Undifferentiated/Prolymphocytic Leukem ias in 
first or subsequent CR . 
Chronic myelogenous leukemia  in chronic or accelerated 
phase, or CML blast crisis in morphological remissi on (<5% 
blasts) : Chronic phase patients must have failed at least two 
tyrosine kinase inhibitors  been intolerant to all available TKIs or 
have T315I  mutation.  
Myelodysplastic syndrome : IPSS INT -2 or High Risk; R -IPSS 
High or Very High; WHO classification: RAEB -1, RAEB -2; Severe 
Cytopenias: ANC < 0.8, Anemia or thrombocytopenia re quiring 
transfusion; Poor or very poor risk cytogenetics based on IPSS 
or R-IPSS definitions; therapy -related MDS. Blasts must be < 5% 
by bone marrow aspirate morphology.  If ≥5% blasts, patient 
requires chemotherapy for cytoreduction to <5% blas ts prior to 
transplantation.   
MRD positive leukemia (AML, ALL or accelerated/blas t 
phase CML) . Selected patients in morphologic CR, but with 
positive immunophenotypic (flow cytometry) or molecular 
evidence of MRD may be eligible if recent chemother apy has not 
resulted in MRD negative status.  
Leukemia or MDS in aplasia.  These patients may be taken to 
transplant if after induction therapy they remain w ith aplastic bone 
marrow and no morphological or flow -cytometry evidence of 
disease ≥ 28 days post -therapy. These high risk patients will be 
analyzed separately.  
Burkitt’s lymphoma in CR2 or subsequent CR  
Relapsed T -Cell Lymphoma  that is chemotherapy sensiti ve in 
CR/PR that has failed or ineligible for an autologo us transplant.  
Natural killer cell malignancies  
Large -cell lymphoma, Hodgkin lymphoma and multiple 
myeloma  with chemotherapy sensitive disease who are ineligibl e 
for an autologous transplant.  
Relaps ed Chronic lymphocytic leukemia/small lymphocytic 
lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma , 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 14  of 36  CPRC #2015LS149  Follicular Lymphoma  which  have progressed within 12 months 
of achieving a partial or complete remission.  Patients who had 
remissions lasting > 12 months, are eligible after at  least two prior 
therapies.  Patients with bulky disease should be considered for 
debulking chemotherapy before transplant.  Patients w ith 
refractory disease are eligible, unless bulky d isease and an 
estimated tumor doubling time of less than one month .  
Lymphoplasmacytic lymphoma, mantle -cell lymphoma, 
prolymphocytic leukemia  are eligible after initial therapy if 
chemotherapy sensitive.   
Relapsed Multiple Myeloma  that is chemotherapy sen sitive and 
has failed or ineligible for an autologous transpla nt.  
Plasma Cell Leukemia  after initial therapy if achieved at least in 
partial remission; or relapsed and achieved subsequen t 
remission (CR/PR)  
Acquired Bone marrow failure syndromes, except fo r 
Fanconi anemia  
Myeloproliferative Neoplasms/Myelofibrosis.  
Other Leukemia Subtypes:  A major effort in the field of 
hematology is to identify patients who are of high ri sk for 
treatment failure so that patients can be appropriat ely stratified 
to either more (or less) intensive therapy.  This ef fort is 
continually ongoing and retrospective  studies identify new 
disease features or characteristics that are associated w ith 
treatment outcomes.  Therefore, if new features are identified 
after the writing of this protocol, patients can be enrolled with 
the approval of two members of the study com mittee.  
4.1.3  Additional Criteria for Bulky Disease (lymphomas)   
if stable disease  is best response, the largest residual nodal 
mass must < 5 cm (approximately)  
If response to previous therapy , the largest residual mass must 
represent a 50% reduction and be < 7.5 cm (approxim ately)  
4.1.4  Organ Function Criteria  
Adequate organ function is defined as:  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 15  of 36  CPRC #2015LS149  Cardiac: Absence of decompensated congestive heart failure, o r 
uncontrolled arrhythmia and left ventricular ejectio n fraction > 
40%.  For children that are not able to cooperate with MU GA and 
echocardiography, such should be clearly stated in t he 
physician’s note  
Pulmonary: DLCO , FEV 1, FVC  ≥ 40% predicted, and absence of 
O2 requirements. For children that are not able to coop erate with 
PFTs, a pulse oximetry with exercise should be attempte d.  If 
neither test can be obtained it should be clearly s tated in the 
physician’s note.  
Liver:  Transaminases ≤ 5 x upper limit of norm al (ULN) and total 
bilirubin ≤ 2.5 mg/dL except for patients with Gilbert’s syndrome 
or hemolysis   
Renal:   Creatinine ≤ 2.0 mg/dl (adults) and creatinine clearance ≥ 
40 mL/min (pediatrics).    Adults with a creatinine > 1.2 mg/dl or a 
history of renal dysfunction must have estimated creatinine 
clearance ≥ 40 ml/min/1.73m2. 
Adequate performance status is defined as Karnofsky score ≥ 
70% ( ≥ 16 years of age) or Lansky score ≥ 50 (pediatrics)  
4.1.5  Sexually active females  of childbearing  potential and males with 
partners of child -bearing potential must agree to use adequate 
birth control during study treatment .   
4.1.6  Voluntary written consent (adult or parent/guardian  with 
presentation of the minor information sheet, if app ropriate)  
4.2 Exclusion Criteria 
4.2.1  Pregnant or breast feeding. The agents used in this st udy include 
Pregnancy Category D: known to cause harm to a fetu s.  Females 
of childbearing potential must have a negative preg nancy test 
prior to starting therapy.  
4.2.2  Untreated active infection  
4.2.3  Active HIV infection or known HIV positive serology  
4.2.4  Less than 3 months since prior myeloablative transpl ant  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 16  of 36  CPRC #2015LS149  4.2.5  Evidence of progressive disease by imaging modalities  or biopsy 
- persistent PET activity, though poss ibly related to lymphoma, is 
not an exclusion criterion in the absence of CT chan ges indicating 
progression.  
4.2.6  CML in blast crisis  
4.2.7  Large cell lymphoma, mantle cell lymphoma and Hodgk in 
disease that is progressing on salvage therapy.  
4.2.8  Active central nervous system malignancy  
5 Patient Registration In On Core 
Registration will occur after the patient/parent/guar dian has signed the subject 
consent and eligibility is confirmed.  To be eligibl e for registration to this study, 
the patient must meet each criteria listed on the el igibility checklist based on 
the eligibility assessment documented in the patient’ s medical record.  A copy 
of the eligibility checklist is under attachments  within the study in OnCore.  
Patients will be registered in OnCore by the Masonic C ancer Center’s Clinical 
Data Associates (CDA’s).  
At the time of registration in OnCore, the treatment  arm related to statistical 
analysis will be recorded using the followin g definitions:  
Arm 1 (no ATG) - hematologic malignancy patients who have received a 
previous autologous transplant or ≥ 2 cycle s of multi -agent chemotherapy 
within the 3 months previous to UCBT  
Arm 2 (ATG) - hematologic malignancy patients who have not been tre ated 
with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 mont hs 
previous to UCBT, should receive ATG as part of the ir conditioning regimen  
If one or both of the cord blood units used  for the graft is unlicensed, the 
participant will co -enroll on University of Minnesota protocol MT2011 -13R 
“Infusion of Cell Populations from Unlicensed Umbilic al Cord Blood Units” as 
the units used for the transplant will be minimally manipulated.   
6 Treatment Plan  
In order to provide optimal patient care and to acc ount for individual medical 
conditions, investigator discretion may be used in th e prescribing of all 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 17  of 36  CPRC #2015LS149  supportive care drug therapy (i.e. acetaminophen, di phenhydramine, 
antimicrobials, etc.) . 
 
All patients will receive allopurinol 300 mg/day (for peds -150 mg/m2/day) PO, 
unless known allergy ending one day after the last d ose of chemotherapy or 
TBI (may continue longer if clinically indicted) . 
All drugs used in this study are commercially availabl e by prescription.  
6.1 Preparative Regimen  (Arm 1 - no ATG ) 
The administration of the preparative regimen will f ollow institutional drug and 
supportive care guidelines.  Dose and/or schedule adj ustments consistent with 
the standard of care may be made on an individual p atient basis as needed for 
safety.  
 
 
 
 
 
 
 
 
 
Fludarabine  will be administered as a 1 hour infusion per instit utional 
guidelines on Day -6 through Day -2.  Dose adjustments will be made for adult 
patients with renal impairment defined as CrCL < 70m L/minute. Fludarabine 
dose MAY  also be reduced to this dose if there is prior malign ancy involvement 
of the central nervous system with intrathecal chemo therapy and/or cranio -
spinal irradiation  
Cyclophosphamide  will be administered as a 2 hour intravenous infusio n with 
a high volume fluid flush and mesna per institution al guidelines on Day -6.   
Dosing is based on Actual Body Weight (ABW) unless ABW  > 150% abov e 
Ideal Body Weight (IBW), in which case the dose sho uld be computed using 
adjusted body weight.  Treatment Day  Treatment  
Day -7 Begin allopurinol ( Day -7 to Day 0) 
Day -6 Fludarabine 30 mg/m2 IV over 1 hour  
Cyclophosphamide 50 mg/kg IV over 2 hours  
Antiemetics  and fluid flush per institutional guidelines  
Day -5 Fludarabine 30 mg/m2 IV over 1 hour  
Day -4 Fludarabine 30 mg/m2 IV over 1 hour  
Day -3 Fludarabine 30 mg/m2 IV over 1 hour  
Begin MMF and Sirolimus  per section 6.3  
Day -2 Fludarabine 30 mg/m2 IV over 1 hour  
Day -1 TBI 200 cGy  
Day 0  UCB cell infusion (transplant)  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 18  of 36  CPRC #2015LS149  Steroids and/or other medications may be used as need ed per the discretion 
of the treating physician.  
TBI will be administered as a single treatment on Day -1.  Refer to appendix III. 
6.2 Preparative Regimen with ATG  
Patients who have had a prior autologous transplant or who have had ≤ 1 cycle 
of chemotherapy in the previous 3 months should rec eive ATG as part of their 
conditioning regimen.  
 
The administration of the preparative regimen will f ollow institutional drug and 
supportive care guidelines.  Dose and/or schedule adj ustments consistent with 
the standard of care may be made on an individual patient basis as needed for 
safety.  
Fludarabine  will be administered as a 1 hour infusion per instit utional 
guidelines on Day -6 through Day -2.  Dose adjustments will be made for adult 
patients with renal impairment defined as CrCL < 70m L/minute. Fludarabine 
dose MAY  also be reduced to this dose if there is prior malign ancy involvement 
of the central nervous system with intrathecal chemo therapy and/or cranio -
spinal irradiation  
Cyclophosphamide  will be administered as a 2 hour intravenous infusio n with 
a high volume fluid flush and mesna per institution al guidelines on Day -6.   Treatment Day  Treatment  
Day -7 Begin allopurinol (day -7 to day 0)  
Day -6 Fludarabine 30 mg/m2 IV over 1 hour  
Cyclophosphamide 50 mg/kg IV over 2 hours  
ATG 15 mg/kg IV every 12 hours   
Antiemetics and fluid flush per institutional guide lines 
Day -5 Fludarabine 30 mg/m2 IV over 1 hour  
ATG 15 mg/kg IV every 12 hours  
Day -4 Fludarabine 30 mg/m2 IV over 1 hour  
ATG 15 mg/kg IV every 12 hours  
Day -3 Fludarabine 30 mg/m2 IV over 1 hour  
Begin MMF and Sirolimus  per section 6.3  
Day -2 Fludarabine 30 mg/m2 IV over 1 hour  
Day -1 TBI 200 cGy  
Day 0  UCB cell infusion (transplant)  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 19  of 36  CPRC #2015LS149  Dosing is based on Actual Body Weight (ABW) unless ABW  > 150% above  
Ideal Body Weight (IBW), in which case the dose sho uld be computed using 
adjusted body weight.  
Steroids  and/or other medications may be used as needed per t he discretion 
of the treating physician.  
Equine ATG (ATGAM)  15 mg/kg IV will be administered every 12 hours 
beginning on Day -6 and continuing on Day -5 and Day -4 (for a total of 6 doses)  
per institutional guidelines.  Methylprednisone 1 mg /kg IV will be administered 
prior to each dose of ATG per institutional guideli nes.  Additional steroids 
and/or other medications may be used as needed per the discretion of the 
treating physician.  
TBI will be administered as a single treatment on Day -1.  Refer to appendix III. 
6.3 GVHD Prophylaxis (begin Day -3) 
All patients will receive prophylaxis for GVHD with t wo drugs both beginning 
at Day -3 as follows:  
6.3.1  Sirolimus  
Adult Dosing:   Sirolimus  will be administered starting at Day -3 with 8 -12 
mg oral loading dose followed by single dose 4 mg/d ay with a target serum 
concentration of 3 to 12 mg/mL by high -performance liquid chromatography 
(HPLC) and will be monitored per institutional guid elines.   In the absence of 
acute GVHD sirolimus may be tapered starting at Day +100 and eliminated 
by Day +180 post -transplantation.  
Pediatric Dosing:   Sirolimus will be administered starting on Day -3 with 
an oral loading dose of 10 mg  followed by maintenance dosing of 2.5 
mg/m2/day (Maximum total daily dose of 4mg) as per insti tutional 
guidelines. Target serum concentration goals are 3 to 12 mg/mL by high -
performance liquid chromatography (HPLC) and will b e monitored per 
institutional guidelines.   
Due to the long and variable half -life in pediatric patients, it is recommended 
that sirolimus dosing changes must not be made unti l 3 days after a dose 
change or using best clinical judgment.  In the absenc e of acute GVHD 
sirolimus may be tapered starting at Day +100.    
Sirolimus is available as 0.5 mg tablet, 1 mg tablet,  2 mg tablet and 1mg/ml 
oral suspension.  The oral tablets and oral suspens ion are not bio -
equivalent.  No IV formulation is available.  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 20  of 36  CPRC #2015LS149  6.3.2  Mycophenolate Mofetil (MMF)  
Mycophenolate mofetil  (MMF) 3 gram/day IV/PO for patients who are ≥ 40 
kg divided in 2 or 3 doses.  In obese patients (>125% IBW) 15 mg/kg every 
12 hours may be considered.  Pediatric patient (<40 kilograms) will receive 
MMF at the dose of 15 mg/kg/dose every 8 hours beginn ing Day -3.  MMF 
dosing will be monitored and altered as clinically ap propriate based on 
institutional guidelines.  Patients will be eligibl e for MMF dosing  and 
pharmacokinetics studies.  
Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if 
no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days 
of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]).  If no donor engraftm ent, 
do not stop MMF.  
If the patient has acute GVHD requiring systemic th erapy, MMF may be 
stopped 7 days after initiation of systemic therapy for  acute GVHD (e.g. 
resolution of skin rash, vomiting, and diarrhea).  
6.4 Umbilical Cord Blood Thaw and Infusion ( Day 0)  
Cord blood products are thawed and filtered (170 -micron) in the Molecular and 
Cellular Therapeutics (MCT) Lab using the method of Rubinstein et al. [20] 
There will be no processing of the UCB.  
Note:  Unlicensed UCB units will be covered by Univer sity of Minnesota IND 
BB 14797 ( J. Wagner MD  – sponsor/investigator) and therefore will be in 
compliance with mandatory reporting to the FDA for m inimally manipulated 
UCB units.  
Cord blood products are thawed and filtered (170 -micron) in the Molecular and 
Cellular Therapeutics (MCT) Lab using the method of Rubin stein et al.  
Pre-medications and UCB infusion will be per current ins titutional 
policies /guidelines .  The infusion of the first UCB unit should begin w ithin 15 
minutes, and no later than 30 minutes after arrival  on the Unit.  If 2 units are 
used, both cords will be infused within 30 -60 minutes of each other as deemed 
clinically safe by the BMT attending or designee.  
Vital signs will be checked before and after the infus ion, and one hour post 
infusion  per University Of Minnesota  transplant guidelines .  More frequent vital 
signs may be required depending on reactions to the p roduct infusion.   
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 21  of 36  CPRC #2015LS149  6.5 Supportive Care  
Supportive care will be provided per University Of M innesota institutional 
guidelines for transplan t patients including any supportive care research 
protocols.  
All patients will receive standard supportive transf usion care according to 
transfusion committee guidelines or as modified bas ed on clinical parameters.  
Acute and chronic GVHD will be staged and  treated using current University of 
Minnesota BMT program GVHD protocols   
Antimicrobial prophylaxis directed towards bacteria, fungi and viruses will be 
per University Of Minnesota current institutional gu idelines for transplant 
patients.  
6.6 Management of Slow Engraftment or Graft Failure  
Patients with ANC < 1000 any time after cord infusion  will be started on G -CSF 
support at 5 mcg/kg (IV/SQ)(round to vial size) daily until ANC > 2500/μL for 2 
consecutive days. Once a patient has met these criteria , the AN C will be 
monitored and G -CSF restarted if ANC falls to < 1000.  
If no evidence of donor engraftment on the Day +21/28 bone marrow biopsy, 
notify  the unrelated donor ( URD ) search coordinator to pursue back -up graft 
and arrange a follow -up bone marrow biopsy  per current institutional slow 
engraftment guidelines.  
6.7 Follow -up  
Patients will be followed for 2 years post -transplant per the standard of care 
schedule in section 8.   
Follow -up after 2 years will be per the University of Minnes ota standard 
hematopoietic stem cell transplantation protocol for  long -term follow -up.  
7 Expected Toxicit ies of the Treatment Plan  
7.1 Preparative Regimen  
Cyclophosphamide  
Common  Less Common  Rare  
nausea/vomiting  
mucositis  
sterility  
severe suppression of  
blood counts  
diarrhea  hemorrhagic cystitis  
 cardiomyopathy  
skin rash  
SIADH (Syndrome of Inappropriate Anti -
diuretic Hormone)  
 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 22  of 36  CPRC #2015LS149  Cyclophosphamide  
Common  Less Common  Rare  
fluid weight gain/edema  
alopecia  
 
Fludarabine  
Common  Less  Common  Rare  
• severe suppression of  
• blood counts  
• diarrhea  
• anorexia  
• mucositis  
• nausea/vomiting  
• stomatitis  
• osteoporosis  
• dysuria  • chills  
• fever  
• GI bleeding  
• peripheral edema  
 • neurotoxicity  
- agitation and confusion  
- blurred vision  
- peripheral neuropathy  
- hearing loss  
- headache  
- cerebellar syndrome  
- blindness  
- coma  
- weakness  
• depression  
• insomnia  
• hemorrhagic cystitis (except in FA)  
• abnormal renal function test  
• autoimmune hemolytic anemia  
• deep venous thrombosis  
• aneurysms  
• pruritic skin rash  
• abnormal liver function/liver failure  
• constipation  
• transient ischemic attack  
• dysphagia  
• myalgia  
• arthralgia  
• renal  failure  
 
Total Body Irradiation  
Common  Less Common  Rare  
• nausea and vomiting  
• diarrhea  
• cataracts  
• sterility (inability to have 
children)  
• endocrinopathies 
(hormone imbalance due 
to damage to the 
endocrine gland)  
• stunted growth in children  • parotitis (swelling and 
inflammation of the parotid 
gland)  
• interstitial pneumonitis 
(explained below in the 
damage to vital organs 
section)  
• generalized mild reddening of 
the skin  • dysphagia (difficulty 
swallowing)  
• deformities of the backbone 
(vertebrae)  
• nephropathy (numbness or 
tingling in hands and/or 
feet) 
• risk of 2nd malignancy years 
later (when given along 
with chemotherapy)  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 23  of 36  CPRC #2015LS149  Total Body Irradiation  
Common  Less Common  Rare  
• intestinal cramps  
• mucositis (mouth sores)  • veno -occlusive disease (VOD - 
explained below in the damage 
to vital organs section)  
 
Anti-Thymocyte Globulin (ATG)  – ARM 2 ONLY  
Common  Less Common  Rare  
• fever  
• chills  
• leukopenia  
• pain 
• headache  
• abdominal pain  
• diarrhea  
• hypertension  
• nausea  
• thrombocytopenia  
• peripheral edema  
• dyspnea  
• asthenia  
• hyperkalemia  
• tachycardia  • malaise  
• dizziness  
 • severe allergic reaction 
(anaphylaxis)  
 
 
7.2 GVHD Prophylaxis 
Mycophenolate Mofetil (MMF)  Sirolimus  
• pancytopenia  
• headache  
• insomnia  
• electrolyte imbalances  
• leg cramps/bone pain  
• hypertension  
• dizziness  
• hyperglycemia  
• rash 
• nausea/diarrhea  • fast heart rate  
• pain when breathing, feeling short of breath  
• chest pain, feeling weak or tired  
• coughing up blood or mucus  
• feeling like you might pass out  
• pale skin, easy bruising or bleeding, weakness  
• fever, chills, body aches, flu symptoms  
• night sweats, weight loss  
• swelling of face, stomach, hands or feet  
• rapid weight gain  
• pain or burning when urinating  
• slow healing of a wound  
• joint pain  
• nausea, vomiting, diarrhea, constipation, 
stomach pain  
• headache  
• acne or skin rash  
• high triglycerides and cholesterol  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 24  of 36  CPRC #2015LS149   
7.3 UCB Cell Infusion  
With the cell infusion  
• nausea and vomiting  
• possible allergic reaction (including itching, hives, flushing [red face], 
shortness of breath, wheezing, chest tightness, skin ras h, fever, chills, stiff 
muscles, or trouble breathing)  
 
General transplant related ris ks  
• slow recovery of blood counts   
• graft failure  
• Graft -Versus -Host Disease (GVHD)   
• other complications including : 
o damage to the vital organs  
o serious infections   
o relapse of disease or a new blood cancer   
o risk to the unborn  
 
Risks related to using a UCB stem cell source  
• Bacterial/Endotoxin Contamination  of cellular therapy products may 
occur, but rarely cause acute, severe or life threat ening effects. However, 
the onset of high fever (>2ºC or >3.5ºF rise in temp erature), seve re chills, 
hypotension, or circulatory collapse during or immed iately after infusion 
should suggest the possibility of bacterial contamina tion and/or the 
presence of endotoxin in the product.  
• Transmission of Infectious Disease  may occur because cellular therapy 
products are collected from human body and/or tissues.  The donor selection 
criteria do not totally eliminate the risk of transmit ting the agents currently 
tested such as HIV, HTLV, HBV, HCV, CMV, T. pallidum ( Syphilis), West 
Nile Virus, and Trypanosome (Chagas).   For some ot her infectious disease  
there are no routine tests to prevent disease transm ission including 
Parvovirus spp., Plasmodium spp. (Malaria), the coro navirus associated 
with severe acute respiratory syndrome (SARS), and the agents of human 
transmissible spongiform encephalopathies (TSEs).  
  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 25  of 36  CPRC #2015LS149  8 Clinical Care  Activities  
Scheduled evaluations after screening and until engra ftment may be performed +/ -
3 days from the targeted date; assessments performed after engraftment and 
through Day 100 may be done +/ -7 days of the targeted date.   After Day 100 
assessments may be done +/ - 30 days of the targeted date.  In addition, targeted  
days may be altered as clinically appropriate.  
Activity  Pre-BMT  
Work -Up Day 1 To 
Engraftm ent1 Follow -Up Days 
42-100 Follow -Up ( >Day 100 
through Day 720)  
Consent  X    
Medical History  X daily weekly  X (day 180, 360, 720)  
Physical Exam  X daily weekly  X (day 180, 360, 720)  
RT consultation  X    
Karnofsky/Lansky  X  day 100  X (day 180, 360, 720) 
GVHD Assessment   weekly start day 7  weekly, day 100  X (day 180, 360)  
CBC/diff/plt  X daily weekly  X (day 180, 360, 720 ) 
PT/INR X    
Viral Screen  X    
Basic metabolic panel   daily   
Comprehensive 
metabolic panel  X 2x/wk  weekly  X (day 180, 360, 720) 
Testing for anti -HLA 
antibodies3  X    
Urinalysis  X    
eGFR for adults with 
creat > 1.2 or hx or 
renal dysfunction  X    
Pregnancy test for 
FOCBP  X    
BM Biopsy chimerism   BM (day 21 /28) BM (day 100)  BM (day 360, 720)  
Blood chimerism   Patient and UCB  PB (day 21, 28)  PB (day 60)   
Quantitative 
Immunoglobulins4 X  X (day 100)  X (day 360) 
PFT/D LCO X    
MUGA or Echo  X    
Chest CT  X2    
Disease Evaluation  X X(day 21 to 28)  X (day 100)  X (day 360, 720)  
1 engraftment defined as absolute neutrophil count (ANC) ≥ 5 X 108/L for 3 consecutive measurements  
2 Patients with a history of MDS or a history of 2 or  more consecutive inductions/re- inductions to treat 
acute leukemia or CML blast crisis or prolonged neu tropenia of at least 2 months immediately prec eding 
transplant should have a chest CT without contrast to exclude occult fungal infection prior to transpl ant. 
3 obtain as soon as possible once the patient is dete rmined to be a candidate for UCB transplantation in  
order to guide unit selection  
4 May be omi tted at the physician’s discretion  
NOTE: In certain clinical circumstances (e.g. relap sed or terminally ill  patients ) study tests may be omitted at the 
physician’s discretion).  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 26  of 36 CPRC #2015LS149  9 Adverse Event Monitoring, Documentation and Reporti ng 
Toxicity and adverse events will be classified accordin g to NCI's Common 
Terminology Criteria for Adverse Events V 4.0 (CTCAE) .  A copy of the CTCAE 
can be downloaded from the CTEP home page 
http://evs.nci.nih.gov/ftp1/CTCAE/About.html   
FOR UNLICENSED UCB UNITS ONLY: Selected  expected adverse reactions 
determined to be caused by or at least possibly caus ed by the UCB unit s based 
on objective evidence will be reported in an expedi ted manner to the FDA under 
University of Minnesota IND BB -14797 ( J. Wagner, MD  – sponsor/investiga tor). 
9.1 Event Documentation  
Transplant related outcomes and events will be reco rded in the Blood and 
Marrow Transplantation (BMT) database. Events requi ring prompt reporting to 
the University of Minnesota Institutional Review Boa rd (IRB), early stopping 
rule events, and protocol deviations will be documented in OnCore.  
9.2 Adverse Event Reporting  
The SAE Coordinator will provide the Masonic Cancer Center’s Data and 
Safety Monitoring Council (DSMC) with the SAE in an  appropriate format 
depending on the individual SAE (as reported or in a summary format).  
 
  Agency  Criteria for reporting  Timeframe  Form to 
Use Submission 
address/ fax 
numbers  Copy to:  
U of MN IRB  Events requiring prompt reporting including, but no t 
limited  to unanticipated death of a locally enrolled 
subject(s); new or increased risk; any adverse even t  
that require a change to the protocol or consent 
form or any protocol deviation that resulting in ha rm  
For a complete list refer to 
http://www.research.umn.edu/irb/guidance/ae.htm
l#.VC7xraI0 -sh  Within 5 
business 
days of 
event 
discovery  
 Report 
Form  irb@umn.edu  
 
SAE Coordinator  
mcc-saes@umn.edu  
Masonic 
Cancer 
Center  SAE 
Coordinator Events that impact the early study stopping rules . At time of 
reporting  Event 
Form  SAE Coordinator  
mcc-
saes@umn.edu  n/a 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 27  of 36  CPRC #2015LS149  10 Study Data Collection and Monitoring  
10.1 Data Collection  
This study will track  SAE’s, stopping rule events, and clinical deviations using 
The Online Enterprise Research Management  Environment (OnCoreTM), a web 
based Oracle® database utilizing study specific electronic case repo rt forms.   
All transplant related outcomes and complications wi ll be recorded in the Blood 
and Marrow Transplantation (BMT) database.  
10.2 Data and Safety Monitoring  
The study’s Data and Safety Monitoring Plan will be in compliance with the 
University of Minnesota Masonic Cancer Center's Data &  Safety Monitoring 
Plan (DSMP), which can be accessed at https:/ /z.umn.edu/dsmp . 
For the purposes of data and safety monitoring, thi s phase II study is classified 
as moderate risk .  Therefore , the following requirements will be fulfilled:  
 The Masonic Cancer Center Data and Safety Monitoring Cou ncil (DSMC) 
will review the trial’s progress twice yearly  
 The PI will comply with at least twice yearly monitor ing of the project by the 
Masonic Cancer Center monitoring services.  
 The PI will oversee the submission of all reportable a dverse events per the 
definition of reportable  in section 9. 2 to the Masonic Cancer Center’s SAE 
Coordinator  and the University of Minnesota IRB.   
 
In addition, at the time of the continuing review wi th the University of Minnesota 
IRB, a copy of the report with any attachments will be submitted to the Cancer 
Protocol Review Committee (CPRC).  
10.3 Study Related Monitoring  
The investigator will permit study -related monitoring, audits, and inspections by 
the IRB, government regulatory bodies, and Universit y of Minnesota 
compliance groups.  The investigator will make avail able all study related 
documents (e.g. source documents, regulatory documents, data collection 
instruments, study data, etc.).  The investigator wil l ensure the capability for 
inspections of applicable study -related facilities (e.g. pharmacy,  diagnostic 
laboratory, etc.) will be available for trial relat ed monitoring, audits, or regulatory 
inspections.  
10.4 Record Retention  
The investigator will retain study records for at 6  years after the study file is 
closed with the IRB and FDA.   
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 28  of 36  CPRC #2015LS149  In addition,  the Clinical Trials Office (CTO) will keep a master lo g of all patients 
participating in the study with sufficient informatio n to allow retrieval of the 
medical records for that patient.  
Please contact the CTO before destroying any study related records.  
11 Statistical Considerations  
We have extensive experience with the use of Cy/Flu/ TBI as a non -myeloablative 
conditioning regimen in conjunction with the use of  transplantation of umbilical cord 
blood from unrelated donors in patients with hematolo gical disease. We also have 
extensive experience using CsA/MMF as a GVHD prophylaxis. However, we have 
limited experience with the use of Sirolimus/MMF, sh owing safety and potential 
efficacy. Our principal objective in this study  is to estimate the rate of grade II -IV 
AGVHD using Sirolimus/MMF as a GVHD prophylaxis. Sirolimus/MMF  is preferable 
to CsA/MMF due to its ability to  support  nTreg cells which can potentially reduce 
GVHD and promote immune reconstitution.   
11.1 Primary, Secondary and Transplant -Related Endpoint s and Study 
Design  
Our primary endpoint is the probability of grade II -IV acute GVHD by Day 100. 
Secondary endpoints include transplant related morta lity at 6 months, the 
incidence of grade III -IV acute GVHD at 100 days, c himerism at Day 21, 
100,180 and 365  and the I ncidence of neutrophil engraftment by Day 42. Other 
transplant related endpoints  include the Incidence of platelet engraftment by 
six months , the i ncidence of Day 100 gr ade II -IV and III -IV acute GVHD, the 
incidence of one year chronic GVHD , the p robability of one and two  year 
progression free survival, the probability of one and  two year survival and the 
incidence of one and two year relapse or diseas e progression.   
This is a Minimax two -stage phase II design. Stage 1 will enroll 110 patie nts. If 
54 or fewer  develop GVHD, 45 additional patients will be enroll ed. After stage 
2, if 71 or fewer out of 155 enrolled develop GVHD , CSA/Sirolimus will be 
considered worthy of further consideration.   
 
11.2 Statistical Analysis  
11.2.1  Analysis of Primary Endpoint  
Simple proportions will be used to estimate the pro bability of grade II -IV 
AGVHD . We do not expect competing risk but if necessary AGV HD will 
be estimated by cumulative incidence treating non -event death as a 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 29  of 36  CPRC #2015LS149  competing risk. Ninety -five percent confidence intervals will help provide 
inference as well as show a potenti al upper bound  for the primary 
endpoint  around  the benchmark rate of 42%.  
11.2.2  Analysis Of Secondary and Transplant Related Objectives  
Analyses of the secondary and transplant related end points  emphasize  
estimation along w/ a measure of precision which incl udes 95% 
confidence intervals. Grade II I-IV acute and chronic GVHD will be 
estimated by cumulative incidence treating non -GVHD death as a 
competing risk. Transplant -related mortality will be estimated by 
cumulative incidence treating relapse as a compe ting risk.  Kaplan -
Meier curves will be used to estimate overall and di sease -free survival. 
Engraftment will also be estimated by cumulative inc idence treating non -
event death as a competing risk. Ninety -five percent confidence 
intervals will help provide inference for all endpoints. Chimerism 
(percentage donor) will be summarized among evaluable  patients 
surviving to each time -point at Days 21, 100, 180 and 365 with 
descriptive box -plots and statistics such as medians, ranges and 
interquartile ranges.  
Estimation of endpoints  is the primary emphasis in this study. However, in the 
event that investigators desire to compare primary and/or secondary endpoints 
to an external cohort or wish to look for various risk fact ors within the cohort, 
regression methods will be employed. Cox regression w ill be used for the 
endpoints of survival and disease -free survival. Fine and Gray regression will 
be employed for all endpoints that include competing  risks. Logistic  regression 
will be employed for binary endpoints. SAS 9.3 (SAS Institute, Cary, NC) and 
R 3.0.2 (R foundation for Statistical Computing, Vien na, Austria) will be used 
for all statistical analyses.  
11.3 Rationale for Sample Size  
The sample siz e is based on the Minimax two -stage design with a type -I error 
of 5% and a power of 80%. Using prior data and on advice  by investigators, we 
used a  benchmark rate of 42% GVHD to be considered  effective  and a rate of 
52% or higher to be considered ineffective . Based on our design, t here is less 
than a 5% probability of concluding effectiveness i f the true rate is ≥ 52% . 
GVHD less than equal to 42% is considered effective and there is a n 80% 
probability of concluding effectiveness if the true p roport ion is ≤ 42%. If the trial 
reaches stage 2, there will be 1 55 patients enrolled. We do not expect early 
competing risk for the primary endpoint but if up to  5% of patients have an early  
competing risk of non -event death , we will conservatively  add an addit ional 8 
patients to the study sample for a total enrollment of 163. Based on enrollment 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 30  of 36  CPRC #2015LS149  in the similar trial, MT2005 -02, we can expect to enroll approximately 15 -25 
patients per year so enrollment should be complete b etween 6 and 10 years.  
11.4 Safety Monitoring  
Sirolimus/MMF has been shown to be safe  in protocol MT2005 -02 therefore  
continuous monitoring will not be in place during th is study. Instead, safety will 
be the responsibility of the DSMC committee  and the principal investigator. The 
committee  will review safety twice a year with particular atten tion paid to graft 
failure by Day 42  post-transplant. Graft failure should be estimated at ea ch 
review. A failure rate exceeding 25% should raise concern. If th is rate is 
exceeded, the principal investigator  and any others deemed necessary by the 
DSMC committee should be notified . 
12 Conduct of the Study  
12.1 Record Retention  
The study will be conducted in accordance with the appropriate regulatory 
requirement(s).  Essential clinical documents will be m aintained to demonstrate 
the validity of the study and the integrity of the data collected.  Master files 
should be established  at the beginning of the study, maintained for the du ration 
of the study and retained according to the appropri ate regulations.   
12.2 Ethical Considerations  
The study will be conducted in accordance with ethic al principles founded in 
the Declaration of Helsinki.  The IRB will review al l appropriate study 
documentation in order to safeguard the rights, safet y and well -being of the 
patients.  The study will only be conducted at sites  where IRB approval has 
been obtained.  The protocol, consent, written info rmation given to the patients, 
safety updates, annual progress reports, and any revis ions to these documents 
will be provided to the IRB by the investigator.   
12.3 Informed Consent  
All potential study participants will be given a cop y of the IRB -approved consent 
to review. The investigator or designee will explain all aspects of the study in 
lay language and answer all questions regarding the  study. If the participant 
decides to participate in the study, he/she will be a sked to sign and date the 
consent document. In the case of minor patients, the parent/guardian w ill be 
required to sign and date the parental consent form  and the minor, if 8 years or 
older will be presented with a minor information she et. 
Patients who refuse to participate or who withdraw fr om the study will be treated 
without prejudice.   
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 31  of 36  CPRC #2015LS149  13 References  
1. Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen  KK, Champlin RE, et al. 
Reduced -intensity conditioning transplantation in acute leu kemia: the effect of source of 
unrelated donor stem cells on outcomes. Blood. 2012 ;119(23):5591 -8. 
2. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa  LJ, Wu J, et al. Alternative donor 
transplantation after reduced intensity conditionin g: results of parallel phase 2 trials 
using partially HLA -mismatched related bone marrow or unrelated double umbilical cord 
blood grafts. Blood. 2011;118(2):282 -8. 
3. Rio BC, S.; Vigouroux, S.; Chevallier, P.; Furst, S.; Sirvent, A.; Bay, J.O.; Socie, G.; 
Ceballos, P.; Huynh, A.; Cornillon, J.; Francois, S .; Legrand, F.; Yakoub -Agha, I.; Michel, 
M.; Maillard, N.; Margueritte, M.; Maury, S.; Uzuno v, M.; Bulabois, C.E.; Michallet, M.; 
Clement, L.; Dauriac, C.; Bilger, K.;  Simon, T.; G luckman, E.; Milpied, N.; Rocha, V. . 
Reduced Intensity Conditioning Regimen Prior to Unr elated Cord Blood Transplantation 
In Patients with Acute Myeloid leukemia : Prelimina ry Analysis of a Prospective Phase II 
Multicentric Trial on Behalf of Societe Française D e Greffe De Moelle Osseuse Et 
Therapie Cellulaire (SFGM -TC) and Eurocord. . Blood (ASH Annual Meeting Abstr acts). 
2010;116: 911.  
4. Wallet HL, Sobh M, Morisset S, Robin M, Fegueux N, Furst S, et al. Double umbilical 
cord blood transplantation for hematological malign ancies: a long -term analysis from the 
SFGM -TC registry. Experimental hematology. 20 13;41(11):924 -33. 
5. Rio B, Chevret S, Vigouroux S, Chevallier P, Furst S, Sirvent A, et al. Decreased 
Nonrelapse Mortality after Unrelated Cord Blood Tra nsplantation for Acute Myeloid 
Leukemia Using Reduced -Intensity Conditioning: A Prospective Phase II M ulticenter 
Trial. Biology of blood and marrow transplantation : journal of the American Society for 
Blood and Marrow Transplantation. 2015;21(3):445 -53. 
6. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Mil ler JS, Blazar BR, et al. Umbilical 
cord blood tr ansplantation after nonmyeloablative conditioning: impact on transplantation 
outcomes in 110 adults with hematologic disease. Bl ood. 2007;110(8):3064 -70. 
7. Rogosheske JR, Fargen AD, DeFor TE, Warlick E, Aror a M, Blazar BR, et al. Higher 
therapeutic CsA levels early post transplantation r educe risk of acute GVHD and 
improves survival. Bone Marrow Transplant. 2014;49( 1):122 -5. Epub 2013/09/17.  
8. Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esba um K, Holtan S, et al. Higher 
Dose of Mycophenolate Mofetil Re duces Acute Graft -versus -Host Disease in Reduced -
Intensity Conditioning Double Umbilical Cord Blood Transplantation. Biol Blood Marrow 
Transplant. 2015;21(5):926 -33. Epub 2015/02/07.  
9. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, e t al. Infusion of 
ex vivo expanded T regulatory cells in adults trans planted with umbilical cord blood: 
safety profile and detection kinetics. Blood. 2011; 117(3):1061 -70. Epub 2010/10/19.  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 32  of 36  CPRC #2015LS149  10. Yang X, He G, Gong Y, Zheng B, Shi F, Shi R. Mammal ian target of  rapamycin inhibitor 
rapamycin enhances anti -leukemia effect of imatinib on Ph+ acute lymphoblas tic 
leukemia cells. Eur J Haematol. 2014;92(2):111 -20. Epub 2013/10/12.  
11. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT,  Bassett IV, et al. Sirolimus -
based graft -versus -host disease prophylaxis protects against cytomegal ovirus 
reactivation after allogeneic hematopoietic stem ce ll transplantation: a cohort analysis. 
Blood. 2007;110(2):490 -500. Epub 2007/03/30.  
12. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, et al. 
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, 
related donor allogeneic HCT. Blood. 2014;124(8):13 72-7. Epub 2014/07/02.  
13. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S , Herrera M, et al.  Double 
umbilical cord blood transplantation with reduced i ntensity conditioning and sirolimus -
based GVHD prophylaxis. Bone Marrow Transplant. 201 1;46(5):659 -67. Epub 
2010/08/11.  
14. Kornblit B, Maloney DG, Storer BE, Maris MB, Vindel ov L, Hari P, et al. A  randomized 
phase II trial of tacrolimus, mycophenolate mofetil  and sirolimus after non -myeloablative 
unrelated donor transplantation. Haematologica. 201 4;99(10):1624 -31. Epub 
2014/08/03.  
15. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Va go L, Stanghe llini MT, et al. Sirolimus -
based graft -versus -host disease prophylaxis promotes the in vivo expan sion of 
regulatory T cells and permits peripheral blood ste m cell transplantation from 
haploidentical donors. Leukemia. 2015;29(2):396 -405. Epub 2014/06/05.  
16. Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Dee g HJ, Doney K, et al. Sirolimus 
in combination with cyclosporine or tacrolimus plus  methotrexate for prevention of graft -
versus -host disease following hematopoietic cell transplan tation from unrelated do nors. 
Biol Blood Marrow Transplant. 2008;14(5):531 -7. Epub 2008/04/16.  
17. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, et al. Sirolimus and 
mycophenolate mofetil as GVHD prophylaxis in myeloa blative, matched -related donor 
hematopoietic cell transplantation. Bone Marrow Tra nsplant. 2012;47(4):581 -8. Epub 
2011/05/10.  
18. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT,  Linden E, et al. Sirolimus is 
associated with veno -occlusive disease of the liver after myeloablative allogeneic stem 
cell transplantation. Blood. 2008;112(12):4425 -31. Epub 2008/09/09.  
19. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of 
ex vivo expanded T regulatory cells in adults trans planted with umbilical cord blood: 
safety profi le and detection kinetics. Blood. 2011;117(3):1061 -70. 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 33  of 36  CPRC #2015LS149  20. Rubinstein, P., et al., Outcomes among 562 recipien ts of placental -blood transplants 
from unrelated donors. N Engl J Med, 1998. 339(22): p. 1565 -77. 
 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 34  of 36  CPRC #2015LS149  Appendix I – Eligibility Checklist 
Eligibility Checklists are now kept in Oncore  
 
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 35  of 36  CPRC #2015LS149   
Appendix I I – Karnofsky Performance Status and Lansky Play Score  
For patients 16 years of age and older:  
Karnofsky Performance Scale  
Percent  Description  
100 Normal, no complaints, no evidence of disease.  
90 Able to carry on normal activity; minor signs or sy mptoms of disease.  
80 Normal activity with effort; some signs or symptoms of disease.  
70 Cares for self, unable to carry on normal activity or to do active work.  
60 Requires occasional assistance, but is able to care  for most of his/her needs.  
50 Requires considerable assistance and frequent medic al care.  
40 Disabled, requires special care and assistance.  
30 Severely disabled, hospitalization indicated.  Deat h not imminent.  
20 Very sick, hospitalization indicated. Death not imm inent.  
10 Moribund, fatal processes progressing rapidly.  
0 Dead.  
 
For patients < 16 years of age:  
Lansky 
Score  Play Score  
100 Fully active, normal  
90 Minor restrictions in physically strenuous activity  
80 Active, but tires more quickly 
70 Both greater restriction of and less time spent in play activity  
60 Up and around, but minimal active play; keeps busy with quieter activi ties 
50 Gets dressed but lies around much of the day, no ac tive play but able to participate 
in all quiet play and activities  
40 Mostly in bed; participates in quiet activities  
30 In bed; needs assistance even for quiet play  
20 Often sleeping; play entirely limited to very passi ve activities 
10 No play; does not get out of bed  
0 Unresponsive  
  
MT2015 -17:  NMA UCBT in hematological diseases    
   
April 25, 2022  Page 36  of 36  CPRC #2015LS149  Appendix III – TBI Guidelines 
 
All patients who have had previous radiation therap y or TBI will be seen by Radiation Oncology 
prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be 
delivered by local guidelines provided the effectiv e dose is equivalent to what is recommended 
in the TBI Guidelines.  
Patients ineligible for this protocol include those  who have had previous irradiation to areas of 
the body such that the Radiation Oncologist feels t hat even a relatively small dose of total body 
irradiation (TBI) cannot safely be given.   
The dose of TBI will be 200 cGy given in a single f raction on Day -1. 
The dose rate will be between 10 -19 cGy/minute prescribed to the midplane of the pat ient at the 
level of the umbilicus.  
The TBI will be delivered with right  and left lateral fields with the patient semi -recumbent in a 
semi -fetal position with their arms at their sides.  
Based on measurement of transverse thickness, alumi num compensators will be used to ensure 
that the dose homogeneity across the fields is with in 10% of the prescribed dose. Usually head/ 
neck, leg and lung compensators are used (although based on calculated mid -mediastinal 
doses, lung compensators are often not needed if th e thickness of the arms, which partially 
shield the lung, are taken into the thickness consideration).  
TBI will be delivered with a linear accelerator usi ng 6, 10, or 18 MV photons. The energy used 
will be based on the calculated dose to midline at points along the patient's torso. The lowest 
energy that give s 90-100% of the prescriptions point dose will be used.  
A beam "spoiler" will be used to ensure a full skin  dose.  
Half value layer lung and kidney blocks will not be  utilized for patients who have not previously 
received total body irradiation.  
Updated 10/2015 by Kathryn Dusenbery, MD  
 
 
 
 
 
 
 